EUVIMEDEUVIMED entdecken
Multizentrische Studie

Clinical Features and Risk Factors of Enfortumab Vedotin–Induced Peripheral Neuropathy in Patients With Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study ( YUSHIMA Study)

Takahiko Soma iD, Hajime Tanaka iD, Yuki Nakamura, Noboru Numao, Masaharu Inoue, Atsushi Yoshinaga, Naoko Kawamura iD, Kenji Tanabe iD, Keita Izumi iD, Takanobu Yamamoto, Sho Uehara, Yuya Maezawa und 8 weitere

International Journal of Urology · 2026

DOI: 10.1111/iju.70329 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Journal of Urology, 2026. Verfasst von Takahiko Soma und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Peripheral Nervous System Diseases, Carcinoma, Transitional Cell, Antibodies, Monoclonal, Urinary Bladder Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Enfortumab vedotin (EV) has emerged as a key agent in the evolving treatment paradigm for metastatic urothelial carcinoma (UC). Although EV‐induced peripheral neuropathy (PN) occurs frequently, its risk factors and detailed clinical course remain unclear.

Methods

This multicenter study included 115 consecutive patients with metastatic UC who were treated with EV monotherapy between 2021 and 2023. The incidence, risk factors, and clinical course of PN were analyzed retrospectively.

Results

The median age was 74 years, and 85 (74%) were male. EV was initiated at a reduced dose of < 1.25 mg/kg in 35 (30%) patients. PN occurred in 29 (25%) patients, with a cumulative incidence of 28% at 1 year following EV induction. The maximum PN grades were 1, 2, and 3 in 9 (7.8%), 17 (15%), and 3 (2.6%) patients, respectively. The median time to PN onset was 2.7 months. In multivariable analysis, higher serum albumin levels and starting EV at full‐dose were significantly associated with PN development. Of the patients who experienced Grade 1 PN and whose doses were maintained, 66.6% progressed to Grade 2 or higher. Of the patients who experienced Grade 2 PN and whose doses were maintained, 82% remained at Grade 2, while 18% ultimately progressed to Grade 3.

Conclusion

Higher serum albumin levels were significantly associated with EV‐induced PN. Appropriate dose reduction may help prevent progression from Grade 2 to Grade 3 PN. Nevertheless, further prospective studies are warranted to determine the optimal dose management strategy for long‐term EV therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Peripheral Nervous System DiseasesCarcinoma, Transitional CellAntibodies, MonoclonalUrinary Bladder NeoplasmsHumansMaleFemaleRetrospective StudiesAgedRisk FactorsMiddle AgedAged, 80 and overIncidenceJapan

Stichwörter der Autor:innen

albuminantibody–drug conjugatesenfortumab vedotinperipheral neuropathyurothelial carcinoma

Substanzen

enfortumab vedotinAntibodies, Monoclonal

Autor:innen und Institutionen

  • Department of Urology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
  • Department of Urology, Institute of Science Tokyo, Tokyo, Japan.
  • Department of Urology, Saitama Cancer Center, Saitama, Japan.
  • Department of Urology, Cancer Institute Hospital, Tokyo, Japan.
  • Department of Urology, Soka Municipal Hospital, Saitama, Japan.
  • Department of Urology, JA Toride Medical Center, Toride, Japan.

ORCID-Profile: Takahiko Soma, Hajime Tanaka, Naoko Kawamura, Kenji Tanabe, Keita Izumi, Masahiro Toide, Ryoji Takazawa, Soichiro Yoshida, Yasuhisa Fujii

Zitieren

APA

Soma, T., Tanaka, H., Nakamura, Y., Numao, N., Inoue, M., Yoshinaga, A., Kawamura, N., Tanabe, K., Izumi, K., Yamamoto, T., Uehara, S., Maezawa, Y., Toide, M., Takazawa, R., Araki, S., Kitabayashi, R., Hirakawa, A., Yoshida, S., Koga, F., & Fujii, Y. (2026). Clinical Features and Risk Factors of Enfortumab Vedotin–Induced Peripheral Neuropathy in Patients With Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study ( YUSHIMA Study). International Journal of Urology. https://doi.org/10.1111/iju.70329

Vancouver

Soma T, Tanaka H, Nakamura Y, Numao N, Inoue M, Yoshinaga A, et al. Clinical Features and Risk Factors of Enfortumab Vedotin–Induced Peripheral Neuropathy in Patients With Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study ( YUSHIMA Study). International Journal of Urology. 2026. doi:10.1111/iju.70329

BibTeX
@article{Soma2026,
  author = {Soma, Takahiko and Tanaka, Hajime and Nakamura, Yuki and Numao, Noboru and Inoue, Masaharu and Yoshinaga, Atsushi and Kawamura, Naoko and Tanabe, Kenji and Izumi, Keita and Yamamoto, Takanobu and Uehara, Sho and Maezawa, Yuya and Toide, Masahiro and Takazawa, Ryoji and Araki, Saori and Kitabayashi, Ryo and Hirakawa, Akihiro and Yoshida, Soichiro and Koga, Fumitaka and Fujii, Yasuhisa},
  title = {Clinical Features and Risk Factors of Enfortumab Vedotin–Induced Peripheral Neuropathy in Patients With Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study ( YUSHIMA Study)},
  journal = {International Journal of Urology},
  year = {2026},
  doi = {10.1111/iju.70329}
}
Kostenlos starten →